Indicator #3 The cost of Financialization: More Spent on Shareholders than R&D (FIGURE 3) Ratio of Spending on R&D vs Shareholder Enrichment for Leading Pharmaceutical Companies 2020-2024 The figure shows the ratio of total spending on R&D versus shareholder enrichment (stock buybacks plus shareholder dividends) for 15 peer companies during the five year period from 2020-2024
This allows controlled, repeated access from a single multi-dose vial within the validated use window
Our reputation is our most important asset
Back Mller, TD, Blher, M, Tschp, M, DiMarchi, iRD (2022) 'Anti-obesity drug discovery: advances and challenges', Nature Review Drug Discovery , 21, 201-23
Our Quality Commitment We stand behind our products with a full quality guarantee
These medications should also be avoided in patients with a history of acute or chronic pancreatitis, which is a painful and potentially fatal inflammation of the pancreas